2,876
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Fluticasone furoate/vilanterol once daily improves night-time awakenings in asthma patients with night symptoms: Post hoc analyses of three randomized controlled trials

, MD, , MD, , PhD, , MD, , MMathStat, , PhD & , MSc show all
Pages 890-897 | Received 10 May 2017, Accepted 13 Jul 2017, Published online: 24 Jul 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Akira Umeda, Tateki Yamane, Taichi Mochizuki, Yasushi Inoue, Kenji Tsushima, Kazuya Miyagawa, Atsumi Mochida, Hiroshi Takeda, Yasumasa Okada & Koich Fukunaga. (2019) Real-world efficacy and problems of once-daily use of inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) in Japanese patients with asthma. Cogent Medicine 6:1.
Read now

Articles from other publishers (2)

A. A. Viesel & I. Yu. Viesel. (2022) Fixed combination of vilanterol triphenatate/fluticasone furoate in the treatment of patients with bronchial asthma and chronic obstructive pulmonary disease: a literature review. Meditsinskiy sovet = Medical Council:21-1, pages 72-78.
Crossref
Henrik Svedsater, Helen A. Doll, Jake Macey, Gail Miles, Lisa Bradshaw & Magdalena Vanya. (2018) Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences. Advances in Therapy 35:9, pages 1378-1399.
Crossref